 |
|
 |
- August 20, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"Cardiovascular disease trials with implications for diabetes: Getting the evidence in the modern era"Prof. Timothy Davis (biography)
English - 2008-02-05 - 35 minutes
|
 | (42 slides) |
Summary :
Professor Davis reviews several cardiovascular trials with implications for diabetes that have been conducted in recent years, with a focus on understanding the results. There are certain potential influences on clinical trials to keep in mind: the decrease in effect size due to the Hawthorn effect on the placebo group and due to more intensive management approaches, and the decrease in the...
Learning objectives :
After viewing this presentation the participant will be able to discuss:
The reasons for recent negative results in CVD trials with implications for diabetes, specifically -
DIGAMI 2
PROACTIVE
FIELD
ASPEN
ASCOT-BPLA
|
|
|
|
| Presentation |
|
"The Indian diabetic diaspora: a cardiovascular time bomb"Dr. Soji Swaraj (biography)
English - 2007-11-16 - 21 minutes
|
| (15 slides) |
Summary :
In this presentation Dr. Swaraj discusses possible reasons for the high diabetes disease burden among people of East Indian origin, and prevention and treatment strategies.
Among countries, India has the highest number of people with diabetes. Among the Indian diaspora or Indians living outside of India, diabetes is more prevalent compared to their caucasian counterparts (1); they...
Learning objectives :
After viewing this presentation the participant will be able to discuss:
- Factors contributing to the high diabetes disease burden in people of East Indian origin
- Possible strategies to address this issue
Bibliographic references :
1. Raj Bhopal et al. Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study BMJ 1999;319:215-220.
2. C. J. K. Henry et al. Glycaemic index of common foods tested in the UK and India British Journal of Nutrition 2007.
|
|
|
|
| Presentation |
|
"CARDIOVASCULAR EFFECTS OF TZD'S: A CARDIOLOGY PERSPECTIVE"Dr. John Amerena (biography)
English - 2007-11-10 - 34 minutes
|
| (47 slides) |
Summary :
In this presentation Dr. Amerena presents a clinical perspective on the cardiovascular-related effects of the insulin-sensitising thiazolidinedione drugs (TZDs/glitazones).
In June of this year, a meta-analysis was published by Nissen and Wolski in The New England Journal of Medicine, entitled “Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from...
Learning objectives :
After viewing this presentation the participant will be able to discuss:
- Feedback on the meta-analysis published by Nissen and Wolski (NEJM 2007)
- Effects of glitazones on atherosclerotic biomarkers and plasma lipids
- Risk of heart failure and TZDs: useful information for clinicians
Bibliographic references :
1. Nikolaus Marx; Johannes Froehlich; Laila Siam; Jochen Ittner; Gerhard Wierse; Arnold Schmidt; Hubert Scharnagl; Vinzenz Hombach; Wolfgang Koenig Antidiabetic PPAR{gamma}-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease Arteriosclerosis, Thrombosis, and Vascular Biology. 2003.
2. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ; GLAI Study Investigators.A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia Diabetes Care 28:1547-1554, 2005.
3. Singh S, Loke YK, Furberg CD.Thiazolidinediones and Heart Failure: A teleo-analysis Diabetes Care Publish Ahead of Print published online ahead of print May 29, 2007.
|
|
|
|
| Presentation |
|
"Hypertension: Where We Have Been and Where We Are Going"Prof. George L. Bakris (biography)
English - 2006-11-11 - 33 minutes
|
| (21 slides) |
Summary :
With the growing epidemic of obesity and the associated increase in the prevalence of diabetes and kidney disease comes an accompanying increase in the incidence of hypertension. Thus, the future portends more cardiovascular events associated with these conditions. This presentation is an overview of where we have been and where we are going with respect to control of hypertension.
Learning objectives :
After viewing this presentation the participant will be able to discuss:
- Trends in the prevalence of hypertension
- Hypertension awareness, treatment and control
- JNC and HWG blood pressure classifications
- Prevalence of prehypertension
- Cardiovascular disease risk factors/markers
- Findings from the TROPHY trial
Bibliographic references :
Beeks, Esther; Kessels, Alfons GH; Kroon, Abraham A; van der Klauw, Melanie M; de Leeuw, Peter W Genetic predisposition to salt-sensitivity: a systematic review. Journal of Hypertension. 22(7):1243-1249, July 2004.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW,Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education
Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560-72.
European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension [published corrections appear in J Hypertens. 2003;21:2203-2204 and J Hypertens.2004;22:435]. J Hypertens. 2003;21:1011-1053.
Kshirsagar AV, Carpenter M, Bang H, Wyatt SB, Colindres RE. Blood Pressure Usually Considered Normal Is Associated with an Elevated Risk of Cardiovascular Disease Am J Med. 2006 Feb;119(2):133-41.
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet. 2002 Dec 14;360(9349):1903-13.
|
|
|
|
| Presentation |
|
"Progress in Heart Failure: Outcomes Trials Resulting in Evidence-Based Interventions"Dr. James Young (biography)
English - 2006-11-11 - 35 minutes
|
| (35 slides) |
Summary :
Progress in our understanding of heart failure can be defined by increasing insight into the enormous morbidity and mortality associated with this syndrome, as well as elucidation of its pathophysiology. Arguably, the “modern” day of heart failure awareness and therapy began in the mid-1960s when the syndrome was characterized more as a systemic cardiovascular disease than simply a problem...
Learning objectives :
After viewing this presentation the participant will be able to discuss:
- The facets of heart failure
- Historical perspectives on heart failure
- The emergence of clinical trials in heart failure
- Modern evolution of heart failure therapies
|
|
|
|
| Presentation |
|
"Role of Noninvasive Imaging in the Approach to Atherosclerotic Disease in Diabetes"Prof. Valentin Fuster (biography)
English - 2006-11-11 - 32 minutes
|
| (58 slides) |
Summary :
What are some strategic priorities concerning diabetes, atherothrombosis and imaging? In this presentation Prof. Fuster talks about the role of non-invasive imaging in the approach to atherosclerotic disease in diabetes.
Cardiovascular medicine is likely to focus more in the future on understanding and protecting health, and priorities may involve enhancing biological defense...
Learning objectives :
After viewing this presentation the participant will be able to discuss:
Atherothrombosis, Diabetes and Imaging: Predicting 8 strategic priorities for 2006-2015:
- From treatment to protecting health
- Three molecular/cell processes to enhance
- Four clinical risk groups to identify and protect
Bibliographic references :
1. Boos CJ, Lip GY, Blann AD. Circulating Endothelial Cells in Cardiovascular Disease J Am Coll Cardiol. 2006 Oct 17;48(8):1538-47.
|
|
|
|
| Presentation |
|
"Large Artery Stiffness and Diabetes"Dr. Bronwyn Kingwell (biography)
English - 2005-06-18 - 44 minutes
|
| (48 slides) |
Summary :
In this presentation Dr. Kingwell talks about large artery stiffness, which is a topic of current interest as it is known to predict cardiovascular outcomes, and is of particular importance in diabetic patients.
Type 2 diabetes is characterised by a stiffening of the large arteries (1). The mechanisms of arterial stiffening are various and can be of a functional or structural type....
Learning objectives :
After viewing this presentation the participant will be able to discuss:
- Physiological consequences of arterial stiffening
- Arterial stiffness in diabetes
- Mechanisms of arterial stiffening
- Implications of large artery stiffness in diabetic patients
- Impact of various therapies on large artery stiffness
Bibliographic references :
1. Miranda T. Schram; Ronald M.A Henry; Rob A.J.M van Dijk; Piet J. Kostense; Jacqueline M. Dekker; Giel Nijpels; Robert J. Heine; Lex M. Bouter; Nico Westerhof; Coen D.A. StehouwerIncreased Central Artery Stiffness in Impaired Glucose Metabolism and Type 2 Diabetes: The Hoorn StudyHypertension. 2004;43:176.
2. Mark E. CooperImportance of advanced glycation end products in diabetes-associated cardiovascular and renal disease American Journal of Hypertension.Volume 17, Issue 12, Supplement 1 , December 2004, Pages S31-S38.
3. Eiji Suzuki, MD, Atsunori Kashiwagi, MD, Yoshihiko Nishio, MD, Katsuya Egawa, MD, Shinya Shimizu, MD, Hiroshi Maegawa, MD, Masakazu Haneda, MD, Hitoshi Yasuda, MD, Shigehiro Morikawa, MD2, Toshiro Inubushi, PHD2 and Ryuichi Kikkawa, MDIncreased Arterial Wall Stiffness Limits Flow Volume in the Lower Extremities in Type 2 Diabetic Patients Diabetes Care 24:2107-2114, 2001.
4. Stéphane Laurent; Pierre Boutouyrie; Roland Asmar; Isabelle Gautier; Brigitte Laloux; Louis Guize; Pierre Ducimetiere; Athanase BenetosAortic Stiffness Is an Independent Predictor of All-Cause and Cardiovascular Mortality in Hypertensive Patients Hypertension. 2001;37:1236.
5. Jacques Blacher, MD; Alain P. Guerin, MD; Bruno Pannier, MD; Sylvain J. Marchais, MD; Michel E. Safar, MD; Gérard M. London, MDImpact of Aortic Stiffness on Survival in End-Stage Renal Disease Circulation. 1999;99:2434-2439.
6. Schram, Miranda T.; Kostense, Pieter J.; van Dijk, Robert A. J. M.; Dekker, Jacqueline M.; Nijpels, Giel; Bouter, Lex M.; Heine, Robert J.; Stehouwer, Coen D. A. Diabetes, pulse pressure and cardiovascular mortality: the Hoorn Study. Journal of Hypertension. 20(9):1743-1751, September 2002.
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
|
|
